Crossmark

PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice

Crossref DOI link: https://doi.org/10.1038/s41598-024-64186-2

Published Online: 2024-06-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jung, Jinkyu

Schneider, Eric L.

Zhang, Wei

Song, Hua

Zhang, Meili

Chou, William

Meher, Niranjan

VanBrocklin, Henry F.

Barcellos-Hoff, Mary Helen

Ozawa, Tomoko

Gilbert, Mark R.

Santi, Daniel V.
License Information

Text and Data Mining valid from 2024-06-19

Version of Record valid from 2024-06-19
More Information

Article History

Received: 31 December 2023

Accepted: 6 June 2024

First Online: 19 June 2024

Competing interests

: Authors E.L.S and D.V.S are employees and hold stock or options in ProLynx, Inc. No other authors have competing interests to declare.

Document is current

Any future updates will be listed below